Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

Literature DB >> 22226018

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

Francis Giles, David Rizzieri, Farhad Ravandi, Ronan Swords, Tove Flem Jacobsen, Susan O'Brien.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22226018 PMCID： PMC4104110 DOI： 10.1016/j.leukres.2011.12.010

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

× No keyword cloud information.

9 in total

1. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.

Authors: K Breistøl; J Balzarini; M L Sandvold; F Myhren; M Martinsen; E De Clercq; O Fodstad
Journal: Cancer Res Date: 1999-06-15 Impact factor: 12.701

2. Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies.

Authors: F J Giles; N Vey; D Rizzieri; F Ravandi; T Prebet; G Borthakur; T F Jacobsen; S Hagen; B Nilsson; S O'Brien
Journal: Leukemia Date: 2012-01-06 Impact factor: 11.528

3. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines.

Authors: Carlos M Galmarini; Finn Myhren; Marit L Sandvold
Journal: Br J Haematol Date: 2008-11-19 Impact factor: 6.998

4. Potential mechanisms of resistance to cytarabine in AML patients.

Authors: Carlos M Galmarini; Xavier Thomas; Fabien Calvo; Philippe Rousselot; Assia El Jafaari; Emeline Cros; Charles Dumontet
Journal: Leuk Res Date: 2002-07 Impact factor: 3.156

5. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.

Authors: A D Adema; N Losekoot; K Smid; I Kathmann; F Myhren; M L Sandvold; G J Peters
Journal: Nucleosides Nucleotides Nucleic Acids Date: 2010-06 Impact factor: 1.381

6. The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues.

Authors: Marit Liland Sandvold; Carlos Galmarini; Finn Myhren; Godefridus Peters
Journal: Nucleosides Nucleotides Nucleic Acids Date: 2010-06 Impact factor: 1.381

7. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.

Authors: A D Adema; A C Laan; F Myhren; I Fichtner; H M Verheul; M L Sandvold; G J Peters
Journal: Int J Oncol Date: 2010-01 Impact factor: 5.650

8. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.

Authors: Carlos M Galmarini; Xavier Thomas; Fabien Calvo; Philippe Rousselot; Muriel Rabilloud; Assia El Jaffari; Emeline Cros; Charles Dumontet
Journal: Br J Haematol Date: 2002-06 Impact factor: 6.998

9. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Authors: I Hubeek; R W Stam; G J Peters; R Broekhuizen; J P P Meijerink; E R van Wering; B E S Gibson; U Creutzig; C M Zwaan; J Cloos; D J Kuik; R Pieters; G J L Kaspers
Journal: Br J Cancer Date: 2005-12-12 Impact factor: 7.640

9 in total

5 in total

1. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.

Authors: Susan O'Brien; David A Rizzieri; Norbert Vey; Farhad Ravandi; Utz O Krug; Mikkael A Sekeres; Mike Dennis; Adriano Venditti; Donald A Berry; Tove Flem Jacobsen; Karin Staudacher; Trygve Bergeland; Francis J Giles
Journal: Br J Haematol Date: 2012-06-15 Impact factor: 6.998